Search research articles
Contact Us
Filters
Showing results (151-160 of 231) with videos related to
Page
of 24
Sort By:
Blood Cancer Journal
|
September 1, 2019
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
Yucai Wang, Kerstin Wenzl, Michelle K Manske, et al.
Leukemia & Lymphoma
|
August 6, 2025
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study
Michael A Superdock, Lisa M Rimsza, Danielle S Wallace, et al.
Blood Advances
|
September 18, 2025
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Colleen A Ramsower, George Wright, Hongli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Blood
|
June 15, 2016
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma
Rebecca L Boddicker, Gina L Razidlo, Surendra Dasari, et al.
Haematologica
|
November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matthew J Maurer, Carla Casulo, Melissa C Larson, et al.
British Journal of Haematology
|
October 8, 2016
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts
Hervé Ghesquières, Beth R Larrabee, Olivier Casasnovas, et al.
American Journal of Hematology
|
April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
Thomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Leukemia
|
March 7, 2020
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
Keenan T Hartert, Kerstin Wenzl, Jordan E Krull, et al.
Cell Reports. Medicine
|
March 1, 2024
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
Jordan E Krull, Kerstin Wenzl, Melissa A Hopper, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 231) with videos related to
Sort By:
Page
of 24
Blood Cancer Journal
|
September 1, 2019
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
Yucai Wang, Kerstin Wenzl, Michelle K Manske, et al.
Leukemia & Lymphoma
|
August 6, 2025
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study
Michael A Superdock, Lisa M Rimsza, Danielle S Wallace, et al.
Blood Advances
|
September 18, 2025
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Colleen A Ramsower, George Wright, Hongli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Blood
|
June 15, 2016
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma
Rebecca L Boddicker, Gina L Razidlo, Surendra Dasari, et al.
Haematologica
|
November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matthew J Maurer, Carla Casulo, Melissa C Larson, et al.
British Journal of Haematology
|
October 8, 2016
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts
Hervé Ghesquières, Beth R Larrabee, Olivier Casasnovas, et al.
American Journal of Hematology
|
April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
Thomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Leukemia
|
March 7, 2020
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
Keenan T Hartert, Kerstin Wenzl, Jordan E Krull, et al.
Cell Reports. Medicine
|
March 1, 2024
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
Jordan E Krull, Kerstin Wenzl, Melissa A Hopper, et al.
Page
of 24